Free delivery on all NHS prescriptions — order now

All Blogs / The Link Between NAD+ and Alzheimer's: Can Metabolic Therapies Slow Dementia?

NAD+

The Link Between NAD+ and Alzheimer's: Can Metabolic Therapies Slow Dementia?

Dayna SheppardDayna Sheppard13 Nov 2026~ 36 minutes
The Link Between NAD+ and Alzheimer's: Can Metabolic Therapies Slow Dementia?

Nicotinamide adenine dinucleotide (NAD+) is a coenzyme that helps cells produce energy, maintain DNA and regulate essential biological processes. Researchers are investigating whether declining NAD+ levels contribute to Alzheimer's disease and whether metabolic therapies, including NAD+ precursors such as nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN), could help protect brain health [1]. Early laboratory research has produced encouraging findings, including improvements in memory in worms and mice, but evidence that NAD+ supplements prevent dementia or slow cognitive decline in people remains limited [2].

Alzheimer's disease is the most common cause of dementia. The Alzheimer's Society estimates that almost a million people in the UK live with dementia, and this number is expected to rise to around 1.4 million by 2040. Understanding the biological processes involved in neurodegeneration is therefore an important area of medical research.

NAD+ supports cellular energy production, DNA repair and the function of mitochondria, which help supply cells with energy. Researchers believe that problems with these processes may contribute to Alzheimer's-like damage in the brain [3]. However, promising results from laboratory research do not necessarily translate into effective treatments for people [4].

This article examines what NAD+ does, how it may relate to Alzheimer's disease, what studies of NR and NMN have found, and whether these supplements are authorised for use in dementia care in the UK. It also explains the importance of established Alzheimer's medicines, evidence-based dementia risk reduction and advice from a GP or pharmacist.

In One Sentence:

NAD+ and its precursors NR and NMN are being investigated as potential ways to support brain energy metabolism and reduce Alzheimer's-related damage, but there is currently insufficient human evidence to show that they can prevent, reverse or slow dementia.

Key Takeaways

  • What is the connection between NAD+ and Alzheimer's disease? Laboratory studies suggest that low NAD+ may contribute to DNA damage, abnormal RNA splicing and mitochondrial problems, although the relationship in people is not fully understood.

  • Can NR or NMN slow cognitive decline? These NAD+ precursors can increase NAD+ levels in some human studies, but convincing evidence that they improve memory or slow dementia is lacking.

  • Are NAD+ supplements approved to treat Alzheimer's disease? No. The MHRA regulates medicines in the UK, and a supplement must not be marketed as an authorised treatment for dementia without the appropriate regulatory status.

  • What should I know about supplement safety? The permitted use and dosage of a supplement depend on its ingredients and UK regulatory status, so check the product information and seek advice from a GP or pharmacist before taking it.

  • What can I do to support brain health? Managing blood pressure, staying physically active, not smoking and addressing hearing problems can help reduce modifiable dementia risk factors.

What is NAD+ and why does the brain need it?

Nicotinamide adenine dinucleotide (NAD+) is a coenzyme found in every cell that helps convert energy from food into usable energy and supports DNA repair, cellular signalling and other essential processes.

The brain has a particularly high energy requirement. Although it accounts for about 2 per cent of body weight, it uses approximately 20 per cent of the body's energy. Neurons depend on a continuous energy supply to communicate, maintain synapses and support memory formation.

NAD+ exists in two main forms: NAD+ and NADH. These forms help enzymes transfer electrons during metabolic reactions. This process is essential for producing adenosine triphosphate (ATP), the molecule cells use to power their activities.

NAD+ also supports processes involved in DNA repair and gene control. However, it is continually used and recycled, so its availability depends on the balance between production, consumption and breakdown.

Energy production

NAD+ helps cells extract energy from nutrients and transfer it into pathways that produce ATP [5].

During food breakdown, NAD+ accepts electrons and becomes NADH. NADH then delivers electrons to the electron transport chain in the mitochondria, supporting oxidative phosphorylation and ATP production. Glycolysis, the Krebs cycle and related metabolic processes all contribute to this energy system.

Mitochondria are often described as the cell's power stations because they produce much of the ATP needed for normal cell function. In the brain, this energy supports electrical signalling, communication between neurons and the maintenance of synapses.

If energy production becomes less efficient, neurons may struggle to maintain these functions. Researchers are investigating whether changes in NAD+ availability contribute to this problem in Alzheimer's disease.

Repair and signalling

NAD+ also provides fuel for enzymes involved in DNA repair, gene regulation and cellular signalling.

A 2019 review in Cell Metabolism examined how NAD+ is produced and consumed, including the roles of PARP1, sirtuins and CD38. PARP1 uses NAD+ during responses to DNA damage, while sirtuins use it to regulate proteins and cellular activity [6]. CD38 is another important consumer of NAD+.

Cells can produce NAD+ through several routes, including pathways involving vitamin B3, tryptophan, NR and NMN. The NAD+ salvage pathway recycles nicotinamide, with the enzyme NAMPT playing a central role in this process.

Another enzyme, SARM1, can promote NAD+ breakdown in injured neurons. This highlights how NAD+ metabolism is connected to both normal cellular maintenance and processes associated with neurological damage.

The NHS explains that most people can obtain the niacin they need through a balanced diet. Recommended daily niacin intake for adults is approximately 16.5mg for men and 13.2mg for women. Foods containing vitamin B3 include meat, fish, eggs and fortified or enriched wheat flour.

Vitamin B3 includes different forms, such as nicotinic acid and nicotinamide [7]. These should not be confused with NR and NMN, which are precursors the body can use to produce NAD+ [8] [9].

Does NAD+ fall as we get older?

NAD+ levels may change with age, but the extent and consistency of this decline in humans remain subjects of scientific investigation.

Ageing is associated with changes in metabolism, DNA repair and mitochondrial function. Some researchers believe that a reduction in NAD+ availability may contribute to these changes. However, findings from animal experiments cannot establish how NAD+ changes in every human tissue or whether increasing it will improve health.

In the brain

A brain-scanning study of healthy volunteers published in PNAS in 2015 reported age-related reductions in brain NAD+, total NAD and the NAD+/NADH redox ratio [10].

The researchers used phosphorus-31 magnetic resonance spectroscopy, known as 31P magnetic resonance spectroscopy, to investigate metabolic compounds in the brain without taking a tissue sample. The findings suggest that age-related changes in brain NAD+ metabolism deserve further study.

However, a change in a biomarker does not automatically indicate that a person will develop Alzheimer's disease. Nor does it demonstrate that taking an NAD+ supplement will reverse the change or prevent cognitive decline.

In the blood

A 2026 study published in Nature Metabolism examined whole-blood NAD+ across seven cohorts, adding to research into the relationship between NAD+ and age [11].

Blood measurements can help researchers identify patterns across groups of people, but they do not necessarily reflect NAD+ concentrations inside the brain. Age, lifestyle and other biological factors may influence the results.

Whole-blood NAD+ is therefore a potential biomarker of ageing rather than a definitive test for brain health or Alzheimer's disease. More research is needed to understand how blood measurements relate to brain metabolism and clinical outcomes.

Across human studies

A 2025 review in Nature Metabolism highlighted limitations in the evidence for a consistent age-related decline in human NAD+ and the clinical effectiveness of NAD+ precursors [12].

Although some studies have reported changes in NAD+ with age, the number of human studies is limited and results vary according to the tissue examined, the population studied and the measurement methods used.

Human trials of NR and NMN have also shown that raising NAD+ does not necessarily produce measurable improvements in health. Researchers must establish whether these changes translate into meaningful benefits, including better memory or a lower risk of neurodegeneration.

How might NAD+ depletion fuel Alzheimer's damage?

NAD+ depletion may contribute to Alzheimer's-related damage by affecting DNA repair, RNA splicing and mitochondrial energy production, although researchers have not established that it is a primary cause of the disease.

The NHS explains that Alzheimer's disease is associated with two abnormal proteins: amyloid-beta, which can form plaques around brain cells, and tau, which can form tangles inside them [13]. These changes are associated with damage to brain cells and the development of dementia symptoms.

A 2025 study in Cell Reports Medicine reported that NAD+ levels were markedly reduced in brain tissue from people with Alzheimer's disease [14]. In mice, an experimental compound called P7C3-A20 restored NAD+ balance and reversed advanced disease-related changes. These findings are scientifically interesting, but the drug was tested in animals rather than established as a treatment for people.

The research raises three important questions about how NAD+ depletion might contribute to neurodegeneration.

The DNA repair trap (PARP1)

The PARP1 enzyme uses NAD+ to help repair DNA damage, but persistent DNA damage may increase NAD+ consumption and place additional pressure on cellular energy production.

DNA breaks can occur during normal cellular activity and in response to damaging processes. PARP1 detects certain types of DNA damage and helps coordinate repair by using NAD+ as fuel. It produces molecules known as poly(ADP-ribose), which help recruit and regulate proteins involved in the repair process.

A UK study of 30 donated brains, published in the journal Brain in 1999, found that poly(ADP-ribose), a marker of PARP activity, had accumulated in all 20 Alzheimer's brains examined and in five of the ten control brains.

This finding suggests that DNA repair activity may be altered in Alzheimer's disease. However, post-mortem brain tissue cannot establish whether increased PARP activity caused the disease or occurred as a consequence of other damage.

A 2018 study published in PNAS investigated NR in mice with weakened DNA repair. NR restored NAD+ balance, reduced DNA damage and inflammation, lowered phosphorylated tau and improved memory. It did not change amyloid-beta.

The results suggest that supporting NAD+ availability could be relevant to certain forms of neuronal damage. However, the experiment involved mice, including models with impaired DNA repair, so it cannot establish whether NR has the same effects in people with Alzheimer's disease.

RNA splicing and toxic tau (EVA1C)

NAD+ may influence RNA splicing, a process that determines how genetic messages are assembled before cells use them to make proteins.

A study published in Science Advances investigated the relationship between NAD+ metabolism, RNA splicing and tau-related damage in worms and two mouse models. The researchers found that NR and NMN corrected certain RNA splicing errors and improved memory in these experimental models.

The study identified EVA1C as an important part of the process. When EVA1C was switched off, the reported benefits disappeared. The researchers also found changes involving EVA1C in donated human Alzheimer's brain tissue.

RNA splicing allows cells to produce different proteins from genetic messages. When this process is disrupted, cells may produce proteins or protein variants that affect normal function. Researchers are investigating whether such errors contribute to toxic tau changes and neuronal damage.

The findings offer a possible explanation for how NAD+ precursors could influence Alzheimer's-like damage. However, the improvements in memory were observed in worms and mice, not in human clinical trials.

The study's lead author also declared professional and commercial links with NAD+ companies, including ChromaDex. Such disclosures do not automatically invalidate research, but they are relevant when assessing the evidence alongside independent replication and human trial results.

Mitochondrial failure

Mitochondrial failure may affect memory by reducing the energy available to neurons and disrupting the synapses that allow brain cells to communicate.

Neurons require substantial amounts of energy to maintain their electrical activity, process information and form memories. Damaged mitochondria can reduce energy production and contribute to cellular stress. These problems may become particularly important in the hippocampus, a brain region involved in learning and memory.

Research into inherited Alzheimer's disease has shown that some biological changes occur years before symptoms become apparent. A 2012 study published in the New England Journal of Medicine found that amyloid-related changes could begin approximately 25 years before expected symptoms, while reduced brain glucose use was detectable around ten years before symptoms in the inherited form studied [17].

These findings indicate that changes in brain energy metabolism may precede noticeable cognitive impairment in some people. They do not show that NAD+ supplementation can prevent these changes.

A 2019 study in Nature Neuroscience examined mitophagy, the process by which cells identify and remove damaged mitochondria [18]. Researchers found impaired mitophagy in the hippocampus of people with Alzheimer's disease. Experimental interventions that improved this process, including approaches involving NAD+, reduced amyloid-beta and tau-related changes and improved memory in worms, mice and laboratory-grown human nerve cells.

These results are encouraging for future research, but laboratory-grown cells are not equivalent to a functioning human brain.

The UK Dementia Research Institute also highlights the importance of synapses in Alzheimer's disease [19]. Loss of synapses is a strong predictor of dementia symptoms, reinforcing the need to understand how cellular energy, neuronal communication and memory are connected.

"Research into NAD+ is helping scientists understand how cellular energy, DNA repair and mitochondrial function may contribute to Alzheimer's disease. However, results from worms, mice and laboratory-grown nerve cells are not enough to establish a treatment for people. Human clinical trials remain essential."

Rachael Clarke MRCPharm, Superintendent Pharmacist, Mail My Meds

How does DNA damage drain NAD+?

DNA damage can increase the activity of repair enzymes such as PARP1, which consume NAD+ as cells attempt to maintain their genetic material.

When DNA damage occurs repeatedly, the demand for NAD+ may rise. If production and recycling cannot keep pace with consumption, cells may have less NAD+ available for energy production and other essential functions.

The relationship is complex. NAD+ depletion can have several causes, and it has not been established as the single mechanism responsible for Alzheimer's disease.

What did the UK study of 30 donated brains find?

The 1999 study in Brain found increased poly(ADP-ribose) in post-mortem tissue from people with Alzheimer's disease, suggesting altered PARP activity [15].

Poly(ADP-ribose) is produced during certain DNA repair responses. The finding is consistent with changes in DNA damage responses in Alzheimer's brains, although it cannot determine whether these changes initiated the disease.

What did the 2018 NIH mouse study show?

A 2018 study published in PNAS found that NR improved NAD+ balance and several measures of brain health in mice with weakened DNA repair [16].

The US National Institutes of Health research reported reductions in DNA damage, inflammation and phosphorylated tau, alongside improvements in learning and memory. Amyloid-beta was not reduced.

These results support further investigation of NAD+ metabolism in neurodegeneration, but the study does not demonstrate that NR treats Alzheimer's disease in people.

How is NAD+ linked to RNA splicing and toxic tau?

NAD+ may influence RNA splicing through biological pathways involving EVA1C, potentially affecting how brain cells produce proteins associated with tau-related damage.

What did the Science Advances study find?

The study published in Science Advances investigated worms, including C. elegans, and mouse models of toxic tau, including P301S tau mice.

Researchers led by Evandro Fei Fang and colleagues found that NR and NMN corrected particular RNA splicing errors and improved memory-related outcomes in these experimental models. The effects depended on EVA1C, suggesting that this protein has an important role in the pathway.

Did NR and NMN correct splicing errors?

Yes, in the experimental models examined, the NAD+ precursors corrected certain splicing errors and improved memory-related outcomes.

However, these results do not establish that taking NR or NMN improves memory in people with Alzheimer's disease. The findings need independent confirmation and testing in appropriately designed human trials.

What did donated human brain tissue show?

The researchers identified alterations involving EVA1C in human Alzheimer's brain tissue.

This provides a potential connection between the laboratory findings and human disease. Nevertheless, identifying a change in donated brain tissue does not show that modifying EVA1C will improve symptoms or slow dementia in living patients.

Were there declared commercial links?

The lead researcher disclosed links with NAD+ companies, including ChromaDex.

Readers should consider these disclosures as part of a balanced assessment of the evidence. Commercial links do not prove that findings are unreliable, but independent studies are important when evaluating claims about supplements and future treatments.

Why does mitochondrial failure matter for memory?

Mitochondrial failure can affect memory because neurons need a continuous supply of energy to maintain synapses and support communication between brain cells.

What is mitophagy?

Mitophagy is the process by which cells remove worn-out or damaged mitochondria.

The Nature Neuroscience study published in 2019 linked impaired mitophagy in the hippocampus with Alzheimer's disease. Researchers investigated approaches to restoring this process, including NAD+-related interventions and other experimental compounds.

The work involved worms, mice and induced pluripotent stem cell-derived neurons, which are laboratory-grown nerve cells made from reprogrammed human cells. Although these models help researchers investigate mechanisms, they do not prove that NAD+ supplements can reverse memory loss in people.

What happens when mitophagy is restored?

In experimental models, improving the removal of damaged mitochondria was associated with reduced amyloid-beta and tau-related changes and improved memory.

Proteins such as PINK1 and Parkin are involved in some mitophagy pathways. These mechanisms are being investigated as possible targets for future therapies, but their clinical usefulness remains uncertain.

Why is synapse loss important?

Synapses are the connections through which neurons communicate, and their loss is strongly associated with dementia symptoms.

The UK Dementia Research Institute highlights synaptic loss as an important predictor of symptoms in Alzheimer's disease. Preserving neuronal communication is therefore a major focus of dementia research, alongside understanding amyloid, tau and cellular energy metabolism.

Can energy changes start before symptoms?

Yes, research into inherited Alzheimer's disease indicates that changes in amyloid biology and brain glucose use can occur years before symptoms develop.

The 2012 New England Journal of Medicine study examined people at risk of inherited Alzheimer's disease. Its findings show that biological changes can precede clinical symptoms, but they do not establish NAD+ supplementation as a way to prevent disease.

Can NAD+ precursors (NR and NMN) slow cognitive decline?

NR and NMN can raise NAD+ levels in some human studies, but there is not yet convincing evidence that they slow cognitive decline or reverse dementia [20].

It is important to distinguish between a change in a biomarker, such as blood NAD+, and a meaningful clinical benefit, such as maintaining memory or independence. A supplement may affect metabolism without improving the symptoms of a neurological condition.

What did the mild cognitive impairment study find?

A small US study published in GeroScience examined NR in 20 people with mild cognitive impairment.

Participants received up to 1g of NR a day for ten weeks. Blood NAD+ increased approximately 2.6-fold and the supplement was reported to be well tolerated, but memory and thinking scores did not significantly change.

Mild cognitive impairment describes measurable problems with thinking or memory that do not necessarily interfere with everyday independence to the same extent as dementia. Not everyone with mild cognitive impairment develops Alzheimer's disease.

The study was small and short, so it cannot rule out every possible benefit or harm. However, it does not provide evidence that NR improves memory or prevents progression to dementia.

What did the NMN trial show?

A trial involving 80 healthy adults aged 40 to 65 investigated NMN doses of 300mg to 900mg a day for 60 days.

The study found that blood NAD+ increased, but it did not test whether memory improved or whether participants were less likely to develop dementia. The trial was co-sponsored by manufacturers, which is relevant when assessing the findings.

The results suggest that NMN can influence NAD+ metabolism, but they do not demonstrate a treatment effect for Alzheimer's disease.

What did the NADPARK study show?

The Norwegian NADPARK study investigated NR in 30 people who had recently been diagnosed with Parkinson's disease [21].

Participants received 1,000mg of NR a day for 30 days. The study reported an increase in brain NAD+ levels, as discussed by Parkinson's UK. However, the study was small and was not designed to establish that NR prevents Alzheimer's disease or reverses dementia.

Parkinson's disease and Alzheimer's disease are different neurological conditions. Results from a Parkinson's trial cannot automatically be applied to people with Alzheimer's disease.

What did the NEAT trial find?

The NEAT trial investigated high-dose nicotinamide, a form of vitamin B3, in people with early Alzheimer's disease [22].

In 47 participants, nicotinamide at 1,500mg twice daily for 48 weeks did not produce a significant improvement in the cerebrospinal fluid marker p-tau231 or other measured spinal fluid markers compared with placebo.

This is important because the study tested a biological outcome associated with tau pathology rather than relying only on a change in blood NAD+. It did not establish that high-dose nicotinamide slows Alzheimer's disease.

Nicotinamide is not the same as NR or NMN, and the results should not be treated as interchangeable evidence for every NAD+ precursor.

What did the NOPARK trial find?

The NOPARK trial investigated whether NR could produce a meaningful clinical benefit in people with early Parkinson's disease over one year.

The trial involved 410 participants who received NR at 500mg twice daily or placebo [23]. The results, reported in JAMA in October 2026, indicated that NR altered NAD+ metabolism but did not provide a clinically meaningful benefit in Parkinson's disease.

This larger, year-long trial is an important reminder that changes in NAD+ metabolism do not necessarily translate into improvements in symptoms or disease progression [24].

The findings concern Parkinson's disease rather than Alzheimer's disease. Nevertheless, they reinforce the need for adequately powered human trials before NAD+-boosting supplements are promoted as treatments for neurodegenerative conditions.

What does the wider evidence mean?

Taken together, human trials show that NR and NMN can affect NAD+ levels, but evidence of a reliable benefit for memory or cognitive decline remains limited.

A registered clinical trial, such as NOPARK, provides useful information about the study's design and intended outcomes. Registration alone does not demonstrate that a treatment works.

Researchers must also consider animal-to-human translation, the duration of treatment, the doses tested and whether benefits persist over time. A supplement that produces a promising result in a mouse model may not have the same effect in people.

A 2025 mouse study reported substantial improvements following treatment with an experimental compound [26]. However, its lead researcher warned that over-the-counter NAD+ precursors could raise NAD+ to levels that might promote cancer in animal models. The researcher also co-founded a company developing the experimental drug.

This is a reason for further investigation, not proof that NAD+ supplements cause cancer in people. The long-term effects of NAD+ supplementation require careful study.

Outcome

Laboratory studies (mice and worms)

Human trials

Amyloid-beta plaquesMixed. Restoring mitophagy, including with NAD+, reduced amyloid-beta in mice, but NR did not change amyloid-beta in another mouse modelNo difference from placebo in spinal fluid amyloid with high-dose nicotinamide (47 people with early Alzheimer's)
TauNR reduced phosphorylated tau, and boosting NAD+ eased tau-related changes through EVA1CHigh-dose nicotinamide for 48 weeks did not lower the tau marker p-tau231
Memory and learningImproved in several mouse and worm modelsNR at 1g a day for 10 weeks did not change memory or thinking scores (20 people with mild cognitive impairment)
Raising NAD+ (bioavailability)NR restored NAD+ balance in the brains of Alzheimer's miceNR raised blood NAD+ 2.6-fold, NMN raised blood NAD+ in healthy adults, and NR raised brain NAD+ in a small Parkinson's study
Slowing the diseaseA drug that restores NAD+ balance, not a supplement, reversed advanced disease in miceNo slowing shown: NR for a year gave no benefit in 410 people with early Parkinson's
SafetySome researchers caution that pushing NAD+ above normal levels may have unwanted effects, based on animal workGenerally well tolerated in trials of up to a year, with side effects similar to placebo

How do NR and NMN differ?

NR and NMN are both NAD+ precursors, but they differ in their chemical structure, the steps involved in NAD+ production and their regulatory status as food supplement ingredients in Great Britain.

Chemistry

NR is nicotinamide riboside, while NMN is nicotinamide mononucleotide; both can contribute to NAD+ production through the body's metabolic pathways.

NR is converted through a pathway involving nicotinamide riboside kinase, while NMN is converted to NAD+ through enzymes including NMNAT. The body's ability to use either precursor depends on several biological factors, and the precise effects of supplementation remain under investigation.

Although both are being studied for their possible effects on brain health, their ability to raise NAD+ does not establish that either can treat Alzheimer's disease.

Human evidence

NR trials have examined healthy adults, people with mild cognitive impairment and people with Parkinson's disease. NMN research has included trials in healthy adults, but there is insufficient evidence to establish that either precursor prevents dementia or slows cognitive decline.

The NMN study involving 80 healthy adults aged 40 to 65 found increases in blood NAD+ after two months of supplementation. It did not assess memory outcomes or establish benefits for people with Alzheimer's disease.

The distinction matters because a change in blood NAD+ is not the same as an improvement in brain NAD+, and neither necessarily means that a person will experience better memory.

UK status

The regulatory position of NR and NMN differs in Great Britain.

Nicotinamide riboside chloride has a novel food authorisation for use in food supplements, subject to specified conditions. The authorised maximum is 300mg a day for adults, reduced to 230mg a day during pregnancy and breastfeeding [27].

The Food Standards Agency's register lists an NMN novel food application at the risk assessment stage [28]. A separate European Food Safety Authority opinion published in 2026 concluded that a particular company's NMN ingredient was safe at up to 300mg a day for adults, excluding pregnant and breastfeeding women [29].

A positive safety opinion for a particular ingredient in the EU is not the same as authorisation for all NMN products in Great Britain. Regulatory requirements and product status must be checked for the relevant market.

What happened when NAD+ boosters were tested in people?

Human trials have shown that some NAD+ boosters change NAD+ metabolism, but studies have not established that they reliably improve memory or slow brain disease.

The results vary according to the substance tested, the population involved and the outcomes measured.

Mild cognitive impairment (2024)

The small GeroScience study of NR involved 20 older adults with mild cognitive impairment who received up to 1g a day for ten weeks.

Blood NAD+ increased approximately 2.6-fold, but memory and thinking scores did not improve significantly. The study was too small to establish whether NR could influence longer-term dementia risk.

Early Alzheimer's disease (2025)

The NEAT trial, published in Neurology, examined nicotinamide in 47 people with early Alzheimer's disease.

Participants received 1,500mg twice daily for 48 weeks. Researchers measured p-tau231 and other cerebrospinal fluid markers, but nicotinamide did not significantly improve the measured markers compared with placebo.

The findings do not support using high-dose nicotinamide as an established treatment for Alzheimer's disease. They also underline why promising findings about NAD+ biology need to be tested against meaningful clinical outcomes.

Parkinson's disease, NADPARK (2022)

The NADPARK study in Norway involved 30 people newly diagnosed with Parkinson's disease.

NR at 1,000mg a day for 30 days increased brain NAD+ levels. The results were an early indication that oral NR could influence brain metabolism, but the study did not establish a reliable improvement in symptoms or demonstrate a benefit for Alzheimer's disease.

Parkinson's disease, NOPARK (2026)

The NOPARK trial involved 410 people with early Parkinson's disease and compared NR at 500mg twice daily with placebo over one year.

The reported results showed changes in NAD+ metabolism but no clinically meaningful benefit. This larger trial provides important evidence that increasing NAD+ does not necessarily slow a neurological disease.

Although the findings cannot directly answer whether NR affects Alzheimer's disease, they demonstrate why clinical trials must measure symptoms and function rather than relying solely on biochemical changes.

How can you judge NAD+ headlines?

You can judge NAD+ headlines more accurately by checking whether the findings come from people or animals, whether researchers measured blood or brain NAD+, what dose was used and whether independent studies support the claims.

People or animals?

Claims of full recovery from Alzheimer's disease often refer to animal experiments rather than human trials.

A mouse recovering from a memory-related task does not establish that a person with dementia can regain lost memories or independence. Human studies must examine safety, symptoms and meaningful clinical outcomes.

Blood or brain?

Blood NAD+ measurements do not necessarily show how much NAD+ is available in the brain.

A supplement may raise blood levels without producing a meaningful change in brain function. Researchers need to establish whether biochemical changes are associated with better memory or slower cognitive decline.

What dose?

The dose used in a laboratory study may not be appropriate for a commercially available supplement.

For example, some human trials have used 1,000mg of NR a day, while the authorised maximum for NR chloride in Great Britain is 300mg a day for adults in food supplements. The trial dose and the permitted supplement limit serve different purposes, so a study dose should not be treated as a recommendation for self-treatment.

Who benefits?

Researchers' financial relationships are relevant when interpreting NAD+ headlines.

The EVA1C study disclosed links involving NAD+ companies, while the lead researcher of a separate 2025 mouse study co-founded a company developing the experimental drug he investigated. These disclosures do not automatically invalidate the findings, but they make independent replication and transparent reporting particularly important.

The experimental drug P7C3-A20 is not the same as an over-the-counter NR or NMN supplement. Evidence about one compound should not be used to make unsupported claims about another.

Are NAD+ supplements approved for Alzheimer's in the UK?

NAD+ supplements are not established or approved treatments for Alzheimer's disease in the UK, and products must not make unauthorised medicinal claims.

The Medicines and Healthcare products Regulatory Agency (MHRA) determines whether a product is a medicine or falls under another regulatory category. The legal requirements depend on the product's composition, presentation and intended use.

What does MHRA guidance say?

The MHRA's guidance on borderline products explains that a product presented as preventing or treating a disease may be classed as a medicinal product [30].

Medicines generally require the appropriate authorisation before they can be marketed for a particular use. Food supplements are subject to food law and must not be presented as though they have a medicinal licence when they do not.

A product's availability for purchase does not demonstrate that it has been approved to prevent or treat dementia.

Which Alzheimer's medicines are available through the NHS?

The NHS lists donepezil, galantamine and rivastigmine for some people with early to mid-stage Alzheimer's disease, and memantine for some people with moderate or severe disease.

These are established medicines used under appropriate clinical supervision. They may help manage symptoms, but they do not cure Alzheimer's disease.

Treatment decisions depend on the person's diagnosis, stage of disease, other health conditions and individual circumstances. Newer treatments may have separate eligibility criteria and regulatory requirements, so a specialist should provide up-to-date advice about available options.

What does the Alzheimer's Society say about supplements?

The Alzheimer's Society warns against unsupported claims that supplements can prevent, slow or reverse dementia [31].

A supplement marketed for general nutritional purposes should not be confused with a proven dementia treatment. If you are considering NR, NMN or another NAD+ product because of memory concerns, discuss the evidence and potential risks with a healthcare professional rather than replacing prescribed treatment.

Is NR or NMN legal to buy in the UK?

The legal status of an NR or NMN product depends on its ingredients, authorisations, intended use and the part of the UK in which it is sold.

NR chloride

Nicotinamide riboside chloride is authorised as a novel food ingredient for food supplements in Great Britain, subject to specific conditions.

The authorised maximum daily intake is 300mg for adults and 230mg during pregnancy and breastfeeding. Consumers should check the actual ingredient, dose and product labelling rather than assuming that every product containing NR complies with the same requirements.

NMN

NMN's regulatory position differs from that of NR chloride.

The Food Standards Agency register lists an NMN novel food application at the risk assessment stage. A favourable EFSA safety opinion for a particular ingredient does not automatically establish that every NMN product is authorised for sale in Great Britain or Northern Ireland.

If you are considering buying NMN, check the current regulatory status for the relevant UK market and the specific product. Do not assume that availability online confirms legal authorisation.

Nicotinamide and niacin (vitamin B3)

Nicotinamide and niacin are forms of vitamin B3 that contribute to normal nutritional needs and NAD+ metabolism.

The NHS states that most people can obtain adequate niacin through a balanced diet. It also notes that 500mg or less of nicotinamide a day is unlikely to cause harm for most people, while high-dose nicotinic acid can cause flushing and prolonged high intake may damage the liver.

These general nutritional points do not establish the safety of every high-dose product or mean that vitamin B3 treats Alzheimer's disease.

NAD+ injections and drips

NAD+ injections and intravenous (IV) drips are offered by some private providers, but they should not be assumed to be approved treatments for dementia.

The regulatory status depends on the product and how it is supplied and promoted. An injection or infusion may involve different risks from an oral food supplement, and claims about Alzheimer's treatment require appropriate evidence and regulatory authorisation.

Before considering such a service, ask about the product's regulatory status, the qualifications of the provider, potential adverse effects and the evidence supporting the proposed use.

Booster

UK status

UK limit or NHS guidance

Daily dose in brain trials

Nicotinamide riboside (NR)Authorised for food supplements as NR chlorideUp to 300mg a day for adults (230mg in pregnancy and breastfeeding)1,000mg (mild cognitive impairment and Parkinson's trials)
Nicotinamide mononucleotide (NMN)Not yet authorised in Great Britain; Food Standards Agency risk assessment in progressNo UK limit set; EFSA judged 300mg a day safe for adults (EU)Not tested in the trials described in this article
Nicotinamide (vitamin B3)Sold as a vitamin B3 supplementNHS: 500mg a day or less is unlikely to cause harm3,000mg (NEAT early Alzheimer's trial)

Are NAD+ supplements safe?

NR has been reasonably well tolerated in several short-term human studies, but evidence about long-term safety, high doses and use in people with complex health needs remains limited.

What side effects have been reported in trials?

Some NR studies have reported reasonable tolerability, including studies involving people with mild cognitive impairment and Parkinson's disease.

However, small trials may not detect uncommon adverse effects. The absence of a serious safety signal in a short study does not prove that prolonged use is safe for everyone.

Can vitamin B3 cause side effects?

High doses of nicotinic acid can cause skin flushing and may cause liver damage with prolonged use.

Nicotinamide has a different side-effect profile, but high doses should not be treated as harmless simply because it is a vitamin. The dose, formulation, duration of use and person's health all matter.

Is there a cancer risk?

Some animal research has raised questions about the effects of excessive NAD+ precursor intake in particular biological settings.

These findings do not establish that NAD+ supplements cause cancer in people. They do, however, highlight the need for research into long-term effects and the importance of avoiding unsupported claims about safety or anti-ageing benefits.

What about pregnancy and breastfeeding?

The authorised maximum for NR chloride in Great Britain is 230mg a day for food supplements during pregnancy and breastfeeding.

This regulatory limit is not a recommendation to take NR during pregnancy. Anyone who is pregnant, breastfeeding or planning a pregnancy should seek advice from a healthcare professional before using supplements.

When should you speak to a pharmacist?

Ask a pharmacist or GP before starting NAD+ supplements if you take regular medicines, have a long-term condition or are pregnant or breastfeeding.

A pharmacist can help you check the ingredients, assess possible interactions and explain whether the available evidence supports your intended use. In the UK, suspected side effects associated with medicines or certain healthcare products can also be reported through the MHRA's Yellow Card scheme.

Do not stop prescribed Alzheimer's medicines or other regular treatments to replace them with NAD+ supplements.

What can you do now to lower your risk of dementia?

You can help reduce your risk of dementia by addressing modifiable risk factors, although no single lifestyle change can guarantee that you will avoid Alzheimer's disease.

The 2024 Lancet Commission on dementia reported that 14 modifiable risk factors could account for around 45 per cent of dementia cases worldwide [32]. The NHS similarly explains that around four in ten cases may be preventable or delayed by addressing risk factors [33].

These estimates apply to populations, not individual predictions. They do not mean that every case of dementia can be prevented or that lifestyle changes will eliminate the risk.

Manage blood pressure, cholesterol and blood sugar

High blood pressure, high LDL cholesterol and diabetes are important health factors to address as part of a dementia risk reduction plan.

Follow advice from your GP about monitoring blood pressure, cholesterol and blood sugar. If you have been prescribed medicines for these conditions, take them as directed and attend recommended health checks.

Stay active, stop smoking and moderate alcohol intake

Regular physical activity supports general health and can help address some dementia risk factors.

Choose activities that suit your ability, such as walking, cycling, swimming or strength exercises. If you smoke, seek support to stop. If you drink alcohol, follow NHS guidance and avoid excessive consumption.

Look after your hearing and vision

Hearing loss is a recognised modifiable dementia risk factor, so seek a hearing test if you notice changes.

Hearing aids may help when appropriate. Vision problems should also be assessed and treated where possible, as vision loss was included as an additional risk factor in the 2024 Lancet Commission.

Eat a balanced diet

A balanced diet provides the vitamins and minerals needed for normal cellular function, including vitamin B3 for NAD+ production.

Include a variety of vegetables, fruit, wholegrains, protein sources and healthy fats. Mediterranean-style and MIND dietary patterns are being studied for their potential relationship with cognitive health, but neither should be presented as a guaranteed way to prevent Alzheimer's disease.

There is currently no established Alzheimer's prevention diet that can replace wider risk reduction measures or medical care.

Prioritise sleep and general wellbeing

Regular sleep, social contact and support for mental health contribute to overall wellbeing.

Researchers are investigating the gut-brain axis, the gut microbiome and the glymphatic system, which is involved in the movement of fluid and waste products in the brain. However, these areas do not yet provide a basis for claiming that a particular gut health supplement or NAD+ product prevents dementia.

Seek medical advice about memory concerns

Speak to your GP if you or someone close to you experiences persistent or worsening memory problems, confusion or difficulty managing everyday activities.

A GP can assess symptoms, consider other possible causes and arrange further investigations or referral to a memory clinic when appropriate. Depending on the circumstances, assessment may involve blood tests, cognitive assessments and other investigations.

Emerging Alzheimer's biomarkers, including p-tau217, are being studied and used in some clinical pathways, but the appropriate tests depend on the clinical situation and local availability. Do not rely on an unvalidated home test or an NAD+ supplement to diagnose or rule out dementia.

How can Mail My Meds help?

Mail My Meds is a UK online pharmacy that provides a platform for patients to fulfil eligible new and repeat NHS prescriptions and private prescriptions.

Access to medicines can become particularly important when managing a long-term condition or supporting a relative with dementia. Reliable prescription arrangements can help people keep their medicines available without unnecessary disruption.

Keep regular prescriptions on track

Mail My Meds can help eligible patients manage their regular prescriptions through an online pharmacy service.

For people living with Alzheimer's disease or other long-term conditions, regular medicines may include prescribed dementia treatments, blood pressure medicines and other treatments recommended by their healthcare team. Carers and relatives may also help organise prescription requests where appropriate and with the necessary consent.

In England, the NHS Electronic Prescription Service (EPS) allows most prescriptions to be sent electronically to a nominated pharmacy. NHS Digital has reported that more than 95% of prescriptions in England are produced electronically through the EPS [34].

Patients can use the NHS App and other approved routes to manage aspects of their prescriptions, depending on their circumstances and GP arrangements.

What should you check when choosing an online pharmacy?

Choose an online pharmacy that provides clear information about its registration, prescription process and professional support.

Mail My Meds operates as an online pharmacy, with pharmacy registration details that can be checked through the General Pharmaceutical Council (GPhC). 

Before using any online pharmacy, check its registration, understand how prescriptions are handled and make sure you know how to contact the pharmacy team if you have questions about your medicines.

Can Mail My Meds advise on NAD+ supplements?

The pharmacy team can help with questions about medicines and general supplement considerations, including when it may be appropriate to speak to a GP.

NAD+ supplements should not replace prescribed dementia medicines or established risk reduction measures. If you are taking several medicines, have a long-term condition or are considering a supplement for a specific health concern, ask a pharmacist to help you understand the available information and when further medical advice is needed.

Frequently Asked Questions

What is the link between NAD+ levels and Alzheimer's disease?

Laboratory studies suggest that low NAD+ may be associated with DNA damage, abnormal RNA splicing, toxic tau changes and mitochondrial dysfunction in Alzheimer's disease.

Research involving worms, mice and donated human brain tissue has identified possible biological links, but human evidence has not established that NAD+ depletion is the cause of Alzheimer's disease or that raising NAD+ will slow cognitive decline.

Can taking NMN or NR reverse dementia or cognitive decline?

No convincing human evidence currently shows that NMN or NR reverses dementia or reliably slows cognitive decline.

A small NR study in people with mild cognitive impairment raised blood NAD+ without significantly improving memory and thinking scores. Animal studies have reported encouraging results, but these cannot establish dementia reversal in people. The 410-person NOPARK trial in Parkinson's disease also found no clinically meaningful benefit despite changes in NAD+ metabolism.

Are NAD+ supplements approved by the MHRA for Alzheimer's in the UK?

NAD+ supplements are not established MHRA-approved treatments for Alzheimer's disease.

NR and NMN products may be subject to food supplement rules, but this does not authorise them to be marketed as treatments for dementia. Products presented as preventing or treating disease may fall under medicines regulation and require the appropriate authorisation.

Is NMN legal in the UK?

NMN's status depends on the specific product and the applicable rules in Great Britain or Northern Ireland.

The Food Standards Agency's register lists an NMN novel food application at the risk assessment stage. A positive EFSA safety opinion for a particular NMN ingredient does not automatically mean that all NMN products are authorised throughout the UK. Check the current regulatory status before purchasing.

Does NAD+ decline with age?

Some studies suggest that NAD+ levels decline with age in certain tissues, including the brain, but findings across human studies are not fully consistent.

A 2015 brain-scanning study and a 2026 study examining whole-blood NAD+ across seven cohorts contribute to the evidence. Researchers are still investigating how age, lifestyle and other factors influence NAD+ and whether supplementation produces meaningful health benefits.

What is EVA1C?

EVA1C is a protein associated with a biological pathway investigated in research into RNA splicing, NAD+ and tau-related damage.

A 2025 study found that NR and NMN corrected certain RNA splicing errors and improved memory in worms and mouse models, with the reported benefits depending on EVA1C. Alterations involving EVA1C were also identified in human Alzheimer's brain tissue, but further research is needed to establish its relevance as a treatment target.

Can I get NAD+ from food?

The body makes NAD+ using nutrients including vitamin B3 and tryptophan, which are obtained from food.

Sources of vitamin B3 include meat, fish, eggs and fortified wheat flour. A balanced diet can provide the niacin most people need, according to the NHS. Eating foods that support normal nutrition is different from taking a high-dose NAD+ precursor supplement.

Should I take NAD+ supplements if dementia runs in my family?

A family history of dementia does not automatically mean that you should take NAD+ supplements.

There is insufficient evidence to recommend NR or NMN specifically for dementia prevention, including for people concerned about inherited risk factors such as APOE4. Speak to your GP about your family history and individual risk, and focus on evidence-based measures such as managing blood pressure, staying physically active and stopping smoking. A pharmacist can help you assess supplement information and potential interactions with medicines.

Final Thoughts From Our Superintendent Pharmacist

"NAD+ research is an important area of Alzheimer's research because it may help scientists understand the roles of DNA damage, RNA splicing and mitochondria in brain health. Studies involving worms and mice have reported encouraging findings with NR and NMN, but human evidence remains limited. Trials involving people with mild cognitive impairment have not established a clear memory benefit, while the year-long NOPARK trial found no clinically meaningful benefit from NR in Parkinson's disease. 

These findings show why we must distinguish promising laboratory results from proven treatments. NAD+ supplements should not replace prescribed medicines or established approaches to reducing dementia risk. Consumers should also check UK licensing requirements, the current authorisation status of NMN and the permitted supplement limits for NR. 

If you are concerned about memory, dementia risk or whether a supplement is suitable alongside your medicines, speak to your GP or pharmacist. Managing blood pressure, staying physically active, addressing hearing problems and stopping smoking remain important steps towards better long-term health. Further human trials are needed to establish whether NAD+ therapies have a meaningful role in dementia prevention or treatment."

Rachael Clarke MRCPharm, Superintendent Pharmacist, Mail My Meds

Sources

[1] NAD+ reverses Alzheimer’s neurological deficits via regulating differential alternative RNA splicing of EVA1C | Science Advances

[2] NAD⁺ restores memory in Alzheimer’s’ disease models by correcting RNA errors | EurekAlert!

[3] A randomized placebo-controlled trial of nicotinamide riboside in older adults with mild cognitive impairment | GeroScience | Springer Nature Link

[4] Alzheimer's disease - Treatment - NHS

[5] Appraising the brain's energy budget | PNAS

[6] NAD+ in Brain Aging and Neurodegenerative Disorders - ScienceDirect

[7] Vitamins and minerals - B vitamins and folic acid - NHS

[8] Nicotinamide riboside is uniquely and orally bioavailable in mice and humans | Nature Communications

[9] Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults | Nature Communications

[10] In vivo NAD assay reveals the intracellular NAD contents and redox state in healthy human brain and their age dependences | PNAS

[11] Human whole-blood NAD+ levels do not vary with age or lifestyle interventions | Nature Metabolism

[12] NAD+ precursor supplementation in human ageing: clinical evidence and challenges | Nature Metabolism

[13] Alzheimer's disease - Causes - NHS

[14] Pharmacologic reversal of advanced Alzheimer’s disease in mice and identification of potential therapeutic nodes in human brain: Cell Reports Medicine

[15] Increased poly(ADP-ribosyl)ation of nuclear proteins in Alzheimer's disease - Oxford Academic

[16] NAD+ supplementation normalizes key Alzheimer’s features and DNA damage responses in a new AD mouse model with introduced DNA repair deficiency | PNAS

[17] Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's Disease | New England Journal of Medicine

[18] Mitophagy inhibits amyloid-β and tau pathology and reverses cognitive deficits in models of Alzheimer’s disease | Nature Neuroscience

[19] Spires-Jones Lab | UK DRI

[20] The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial | GeroScience | Springer Nature Link

[21] Vitamin B3 supplement shows early promise for Parkinson's

[22] Phase 2A Proof-of-Concept Double-Blind, Randomized, Placebo-Controlled Trial of Nicotinamide in Early Alzheimer Disease | Neurology

[23] Nicotinamide Riboside for Patients With Early-Stage Parkinson Disease: The NOPARK Randomized Clinical Trial

[24] Submit Studies | ClinicalTrials.gov

[25] Search ClinicalTrials.gov for: | Card Expert Search

[26] New study shows Alzheimer’s disease can be reversed to achieve full neurological recovery—not just prevented or slowed—in animal models | CWRU Newsroom

[27] Nicotinamide riboside chloride

[28] β-Nicotinamide Mononucleotide

[29] Safety of beta-nicotinamide mononucleotide (β-NMN) pursuant the regulation (EU) 2015/2283 and the bioavailability of nicotinamide from this source in the context of Directive 2002/46/EC

[30] Borderline products: how to tell if your product is a medicine - GOV.UK

[31] Can I buy supplements to prevent or treat dementia? | Alzheimer's Society

[32] Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission

[33] Can dementia be prevented - NHS

[34] Electronic Prescription Service - NHS England Digital

About the author

Blog author

Dayna Sheppard

Dayna is a pharmacy manager with over 15 years of pharmacy experience. She is focused on delivering a safe and excellent pharmacy service for patients.

Medically reviewed by

Medical reviewer

Taslima Hussain

Taslima is a pharmacist who is passionate about patient care. She has experience working in community pharmacy as a locum.

Your trusted NHS pharmacy delivering prescriptions across the UK.

Superintendent Pharmacist:

Rachael Clarke

MRCPharm MFRPSI FRSPH

GPhC Reg: 2061366

Premises GPhC Reg: 9011560

Our Prescriber:

Dr Seth Rankin

GMC Registration Number: 4467397

London Medical Laboratory Ltd

CQC Registration Number: 1-21677335073

Prescriptions are issued by London Medical Laboratory Ltd, registered with the Care Quality Commission.

Contact Us

Location

Unit 1, Karmjit House,
Balliol Business Park,
Newcastle upon Tyne NE12 8EW

9am - 5pm

Mon - Fri

Information Commissioner's OfficeProviding NHS servicesVerify LegitScript Approval for www.mailmymeds.co.uk
Pay securely with
card_visa
card_mastercard
card_amex
card_apple
card_google

Mail My Meds
© 2026 MailMyMeds Pharmacy